Literature DB >> 30278940

Toll-like receptor activation as a biomarker in traumatically injured patients.

Marcus D Darrabie1, Jennifer Cheeseman1, Alexander T Limkakeng1, Joseph Borawski1, Bruce A Sullenger1, Eric A Elster2, Allan D Kirk1, Jaewoo Lee3.   

Abstract

BACKGROUND: Surgical insult and trauma have been shown to cause dysregulation of the immune and inflammatory responses. Interaction of damage-associated molecular patterns (DAMPs) with toll-like receptors (TLRs) initiates innate immune response and systemic inflammatory responses. Given that surgical patients produce high levels of circulating damage-associated molecular patterns, we hypothesized that plasma-activated TLR activity would be correlated to injury status and could be used to predict pathological conditions involving tissue injury.
METHODS: An observational study was performed using samples from a single-institution prospective tissue and data repository from a Level-1 trauma center. In vitro TLR 2, 3, 4, and 9 activation was determined in a TLR reporter assay after isolation of plasma from peripheral blood. We determined correlations between plasma-activated TLR activity and clinical course measures of severity.
RESULTS: Eighteen patients were enrolled (median Injury Severity Score 15 [interquartile range 10, 23.5]). Trauma resulted in significant elevation in circulation high mobility group box 1 as well as increase of plasma-activated TLR activation (2.8-5.4-fold) compared to healthy controls. There was no correlation between circulating high mobility group box 1 and trauma morbidity; however, the plasma-activated TLR activity was correlated with acute physiology and chronic health evaluation II scores (R square = 0.24-0.38, P < 0.05). Patients who received blood products demonstrated significant increases in the levels of plasma-activated TLRs 2, 3, 4, and 9 and had a trend toward developing systemic inflammatory response syndrome.
CONCLUSIONS: Further studies examining TLR modulation and signaling in surgical patients may assist in predictive risk modeling and reduction in morbidity and mortality.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Damage-associated molecular pattern; HMGB1; Tissue injury; Toll-like receptor; Trauma

Mesh:

Substances:

Year:  2018        PMID: 30278940     DOI: 10.1016/j.jss.2018.05.059

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

1.  Damage- and pathogen-associated molecular patterns play differential roles in late mortality after critical illness.

Authors:  John Eppensteiner; Jean Kwun; Uwe Scheuermann; Andrew Barbas; Alexander T Limkakeng; Maggie Kuchibhatla; Eric A Elster; Allan D Kirk; Jaewoo Lee
Journal:  JCI Insight       Date:  2019-08-22

Review 2.  Surgical trauma-induced immunosuppression in cancer: Recent advances and the potential therapies.

Authors:  Fan Tang; Yan Tie; Chongqi Tu; Xiawei Wei
Journal:  Clin Transl Med       Date:  2020-01

3.  Midkine Is Elevated After Multiple Trauma and Acts Directly on Human Cardiomyocytes by Altering Their Functionality and Metabolism.

Authors:  Ina Lackner; Birte Weber; Meike Baur; Melanie Haffner-Luntzer; Tim Eiseler; Giorgio Fois; Florian Gebhard; Borna Relja; Ingo Marzi; Roman Pfeifer; Sascha Halvachizadeh; Miriam Lipiski; Nikola Cesarovic; Hans-Christoph Pape; Miriam Kalbitz
Journal:  Front Immunol       Date:  2019-08-21       Impact factor: 7.561

Review 4.  Therapeutic Potential of Mesenchymal Stromal Cell-Derived Extracellular Vesicles in the Prevention of Organ Injuries Induced by Traumatic Hemorrhagic Shock.

Authors:  Guillaume Valade; Nicolas Libert; Christophe Martinaud; Eric Vicaut; Sébastien Banzet; Juliette Peltzer
Journal:  Front Immunol       Date:  2021-09-29       Impact factor: 7.561

Review 5.  Toll-Like Receptor as a Potential Biomarker in Renal Diseases.

Authors:  Sebastian Mertowski; Paulina Lipa; Izabela Morawska; Paulina Niedźwiedzka-Rystwej; Dominika Bębnowska; Rafał Hrynkiewicz; Ewelina Grywalska; Jacek Roliński; Wojciech Załuska
Journal:  Int J Mol Sci       Date:  2020-09-13       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.